Global Regenerative Medicine Partnering Terms and Agreements 2014-2020


The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in regenerative medicine 
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells


The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.


This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.


The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.


The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Regenerative Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2014. The chapter is organized by specific Regenerative Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.


Key benefits


Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of Regenerative Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
  • Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
  • Identify most active Regenerative Medicine dealmakers since 2014
  • Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.


Regenerative Medicine Partnering Terms and Agreements includes:


  • Trends in Regenerative Medicine dealmaking in the biopharma industry since 2014
  • Analysis of Regenerative Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Regenerative Medicine deals
  • Access to Regenerative Medicine contract documents
  • Leading Regenerative Medicine deals by value since 2014
  • Most active Regenerative Medicine dealmakers since 2014


In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Regenerative Medicine Partnering es and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 1100 Regenerative Medicine deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of Regenerative Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
  • Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
  • Identify most active Regenerative Medicine dealmakers since 2014
  • Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Regenerative Medicine dealmaking


2.1. Introduction

2.2. Regenerative Medicine partnering over the years

2.3. Most active Regenerative Medicine dealmakers

2.4. Regenerative Medicine partnering by deal type

2.5. Regenerative Medicine partnering by therapy area

2.6. Deal terms for Regenerative Medicine partnering

2.6.1 Regenerative Medicine partnering headline values

2.6.2 Regenerative Medicine deal upfront payments

2.6.3 Regenerative Medicine deal milestone payments

2.6.4 Regenerative Medicine royalty rates


Chapter 3 – Leading Regenerative Medicine deals


3.1. Introduction

3.2. Top Regenerative Medicine deals by value


Chapter 4 – Most active Regenerative Medicine dealmakers


4.1. Introduction

4.2. Most active Regenerative Medicine dealmakers

4.3. Most active Regenerative Medicine partnering company profiles


Chapter 5 – Regenerative Medicine contracts dealmaking directory


5.1. Introduction

5.2. Regenerative Medicine contracts dealmaking directory


Chapter 6 – Regenerative Medicine dealmaking by technology type


Chapter 7 – Partnering resource center


7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking




Appendix 1 – Regenerative Medicine deals by company A-Z


Appendix 2 – Regenerative Medicine deals by stage of development




Phase I

Phase II

Phase III





Appendix 3 – Regenerative Medicine deals by deal type


Asset purchase


Bigpharma outlicensing


Collaborative R&D







Equity purchase



Joint venture





Material transfer





Spin out



Technology transfer




Appendix 4 – Regenerative Medicine deals by therapy area


Appendix 5 –Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Regenerative Medicine partnering since 2014

Figure 2: Active Regenerative Medicine dealmaking activity– 2014 to 2020

Figure 3: Regenerative Medicine partnering by deal type since 2014

Figure 4: Regenerative Medicine partnering by disease type since 2014

Figure 5: Regenerative Medicine deals with a headline value

Figure 6: Regenerative Medicine deals with an upfront value

Figure 7: Regenerative Medicine deals with a milestone value

Figure 8: Regenerative Medicine deals with a royalty rate value

Figure 9: Top Regenerative Medicine deals by value since 2014

Figure 10: Most active Regenerative Medicine dealmakers 2014 to 2020

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2M, 3D Systems, 3SBio, 4D Molecular Therapeutics, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, Aastrom Biosciences, AAVLife, Abbvie, Abby Grace Foundation, Abcam, AbCellera, Abeona Therapeutics, Abingworth Management, Ablynx, Abzena, Accellix, Accellta, Accenture, Access BIO, AccuResearch, ACEA Biosciences, Actinium Pharmaceuticals, Adaptimmune, Adaptive Biotechnologies, Addex Therapeutics, Adicet Bio, Adva Biotechnology, Advanced Biological Laboratories, Advanced Biologics, Advanced BioMatrix, Advanced BioScience Laboratories, Advanced Biotherapeutics Consulting, Advanced Regenerative Manufacturing Institute, Aelan Cell Technologies, Aevitas Therapeutics, Affinia Therapeutics, AffyXell Therapeutics, AGC Asahi Glass, Agensys, AgeX Therapeutics, Agilent Technologies, Agilis Biotherapeutics, Agrivida, AGTC, AiVita Biomedical, Akashi Therapeutics, Akouos, Akoya Biosciences, Akron Biotechnology, Alcyone Lifesciences, Alder Biopharmaceuticals, Aldevron, Alkahest, Allele Biotechnology and Pharmaceuticals, Allergan, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Alliqua Biomedical, Allogene Therapeutics, AlloVir, Almog Diagnostic, Alnylam Pharmaceuticals, Alpine Immune Sciences, ALS Finding a Cure Foundation, Altor BioScience, ALTuCELL, Amarantus BioSciences, Amarna Therapeutics, Ambys Medicines, American Association of Neuromuscular & Electrodiagnostic Medicine, American CryoStem, American Gene Technologies, American National Multiple Sclerosis Society, American Red Cross, American Society of Hematology, AmerisourceBergen, Amgen, Amicus Therapeutics, AmorChem, Anagenesis Biotechnologies, AnaptysBio, Angiocrine Bioscience, Angionetics, Angiostem, Annapurna Therapeutics, Anthony Nolan, Antibe Therapeutics, Apceth, APEX Biologix, Applied BioMath, Applied DNA Sciences, Applied StemCell, Apricus Biosciences, Araim Pharmaceuticals, Aratana Therapeutics, Arbele, Arbor Biotechnologies, Ariad Pharmaceuticals, Arthrex, Aruvant Sciences, Asahi Kasei, Asana Medical, Ascendance Biotechnology, Ascenion, ASC Therapeutics, Asklepios Biopharmaceutical, Aspect Biosystems, Association for Frontotemporal Degeneration, Astellas Pharma, Astem, Asterand Bioscience, Asterias Biotherapeutics, AstraZeneca, Atara Biotherapeutics, Atelerix, Athersys, Atvio Biotech, Auburn University, Audentes Therapeutics, Audion Therapeutics, Aurora BioPharma, Australian Research Council, Autolus, Avacta, Avactis Biosciences, Avalanche Biotechnologies, Avalon GloboCare, Avectas, Avellino Labs, AveXis, Avita Medical, Avrobio, Avvinity Therapeutics, Axcelead Drug Discovery Partners, Axiogenesis, Axis Therapeutics, AxoSim, Axovant Sciences, Axxam, Azellon Cell Therapeutics, Aziyo Biologics, B-MoGen Biotechnologies, Bacterin International, Bassett Salon Solutions, Bayer, Bayer USA Foundation, Baylor College, Baylor College of Medicine, Baylor Research Institute, B Braun, B Braun CeGaT, Beam Therapeutics, Beckman Research Institute of City of Hope, Beijing Genomics Institute (BGI), Beike Biotech, Bellicum Pharmaceuticals, Ben-Gurion University, Benitec Biopharma, Berkshire Sterile Manufacturing, Berlin-Brandenburg Center for Regenerative Therapies, Beta-O2, Be The Match BioTherapies, Beyond Type 1, BIA Separations, Bill and Melinda Gates Foundation, Bio-Techne, Bio-Tissue, BioAtla, BioBridge Global, BioCanRx, BioCardia, BioCurate, BioCure, BioDlogics, Biogen, BioHeart, BioInvent, BioLamina, BioLife Solutions, Biological Industries, biologistex CCM, BioMarin Pharmaceutical, Biomed, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), BioMed X Innovation Center, Bionic Sight, BioRestorative Therapies, Biosafe, Biosequel, Biosolution, Biotechnology and Biological Sciences Research Council (BBSRC), Biotech Products Services & Research, Bioventus, Bioverativ, Bird Foundation, Bit Bio, Blackstone, Blood Centers of America, Blood Systems Research Institute, Bluebird Bio, BlueRock Therapeutics, Boehringer Ingelheim, Bone Biologics, BoneSupport, Bone Therapeutics, BoyaLife, Bpifrance, BrainStorm Cell Therapeutics, Brammer Bio, BriaCell Therapeutics, BridgeBio Pharma, Brigham and Women's Hospital, Bright Optical, Bristol-Myers Squibb, Broad Institute, Buck Institute for Age Research, Butantan Institute, c-LEcta, C3i, Caladrius Biosciences, Calico, Calidi Biotherapeutics, California Institute for Biomedical Research, California Institute for Quantitative Biosciences (QB3), California Institute for Regenerative Medicine, California Institute of Technology, California State University, California Stem Cell, Calimmune, CAMP4 Therapeutics, Canada-Israel Industrial R&D Foundation, Canadian National Transplant Research Program, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Capricor Therapeutics, Cardiovascular Cell Therapy Research Network, Cardium Therapeutics, CareDx, CareNet, Caribou Biosciences, Carisma Therapeutics, Carnegie Mellon University, Carolina BioOncology Institute, Cartherics, Casebia Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, Castle Creek Pharmaceuticals, Catalan Institute of Nanotechnology (ICN), Catalent, Catapult Therapy TCR, CavoGene LifeSciences, CEA-Leti, Cedars-Sinai Health System, Cedars-Sinai Medical Center, CeGaT, Celdara Medical, Celgene, Cell2in, Celladon, Cell and Gene Therapy Catapult, Cell Applications, Cellaria Biosciences, Cell Care Therapeutics, Cell Cure Neurosciences, Cell Design Labs, Cellect Biotechnology, Cellectis, Cellectis Bioresearch, Cellectricon, CellforCure, CellGenix, Celling Biosciences, CELLINK, Cell Line Genetics, Cell Medica, Cell Mogrify, CellProThera, CellSpring, Celltex Therapeutics, Cellthera Pharma, Cell Therapy, Cell Therapy Catapult, Cellular Biomedicine, Cellular Dynamics International, Cellular Logistics, Cellvation, Celsius Therapeutics, Celtic Biotech, Celularity, Celyad, Censo Biotechnologies, Centauri Therapeutics, Center for Biomarker Research in Medicine, Center for International Blood and Marrow Transplant Research, Center for iPS Cells Research and Application, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Century Therapeutics, Cesca Therapeutics, Cevec Pharmaceuticals, Charite-Universitatsmedizin, Charite Universitatsmedizin Berlin, Chart Industries, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Hospital of Pittsburgh, Children's Medical Research Institute, Children's Research Institute, China-Singapore Guangzhou Knowledge City, China Cord Blood, China Medical System, China Southeast University, ChromaDex, Chugai Pharmaceutical, Cimtech, Cincinnati Children’s Hospital Medical Center, Citius Pharmaceuticals, City of Hope, Cleara Biotech, ClearPoint Neuro, Clearside Biomedical, Clinigen, Clontech Laboratories, Cobra Biologics, Codexis, Cognate BioServices, Collagen Solutions LLC, Collagen Solutions Plc, Collplant, Colorado State University, Columbia University, CombiGene, Connecticut Innovations, Convelo Therapeutics, Cook Biotech, Cooperative Research Centre for Cell Therapy Manufacturing, Copenhagen University Hospital, Copernicus Therapeutics, CORD:USE, Cord Blood Registry, Cordlife, Corestem, Coriell Institute for Medical Research, CorMatrix Cardiovascular, Cosmotec, CPI International, Creative Destruction Lab, Creative Medical Technologies, CRISPR Therapeutics, CROMA Pharma, Cryolife, CryoPort, CSL Behring, CureCell, Cure Duchenne, Cutanogen, Cynata Therapeutics, Cyprium Therapeutics, Cystic Fibrosis Foundation, CytoLumina Technologies, Cytonet, Cytoo, Cytori Therapeutics, CytoSen Therapeutics, Cytovant Sciences, CYTOVIA Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dana-Farber Cancer Institute, DanDrit Biotech, Dartmouth College, Debiotech, DefiniGEN, Defymed, Deloitte, Dendreon, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, DePuy, Derma Sciences, Diabeloop, DigiLab, Dimension Therapeutics, DiNAQOR, Diomics, Direct Biologics, DNA Script, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dr Allen Wu, Duke-NUS Graduate Medical School Singapore, Duke University, DuPont Pioneer, Dyno Therapeutics, Ecole Polytechnique de Montreal, Eden BioCell, EdiGene, Editas Medicine, Eiger BioPharmaceuticals, Elanix Biotechnologies, ElevateBio, Eli Lilly, Elixirgen, Elpis Biomed, EMD Serono, Endocyte, enGene, Engineering and Physical Sciences Research Council, ENPICOM, Enterprise Partners Venture Capital, Enzyvant Science, EpiBone, Epica Medical Innovations, Epic Sciences, Epivax, Eppendorf, ERS Genomics, Erytech, ES Cell International, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Eurostars, Eureka Therapeutic, European Union, Eversana, Evotec, ExcellaBio, ExCellThera, Expression Therapeutics, Exuma Biotech, F1 Oncology, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), Feinstein Institute for Medical Research, Feldan Therapeutics, FerGene, Ferring Pharmaceuticals, FetoLumina Technologies, Fibrocell Science, FIT Biotech, Five Prime Therapeutics, FKD Therapies, FloDesign Sonics, Florey Institute of Neuroscience and Mental Heath, Florida State University, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Forendo Pharma, Formula Pharmaceuticals, Fortis Healthcare, Fortress Biotech, Forty Seven, Fosun Pharmaceutical, Foundation Fighting Blindness, Foundation Medicine, Fraunhofer IGB, Fraunhofer Institute for Molecular Ecology (IME), Fred Hutchinson Cancer Research Center, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm, Fujifilm Diosynth Biotechnologies, Fundacion Progreso y Salud, Gadeta, Gali Klinik, Gamida Cell, GammaDelta Therapeutics, GC LabCell, GE Healthcare, Genable Technologies, GenEdit, Genentech, Generation Biotech, Generex Biotechnology, Gene Therapy Research Institution, Genethon, Genetic Information Research Institute, Genetrix, genOway, Genprex, GenScript USA, GenStem Therapeutics, GenVec, Genzyme, George Washington University, GeoVax, German Red Cross, German Red Cross Blood Donor Service, German Research Foundation (DFG), Gestion Univalor, Gilead Sciences, Ginkgo BioWorks, Gladstone Institutes, GlaxoSmithKline, Global Alliance for Innovation in Neuroscience, GlycoBac, Glycostem Therapeutics, Golden Meditech, Goliver Therapeutics, Government of Canada, Great Ormond Street Hospital (GOSH), Green Cross LabCell, Grifols, Gritstone Oncology, Grunenthal, Guangzhou Xiangxue Pharmaceutical, Gulf Coast Pharmaceuticals, Hadassah Medical Center, Hamad Bin Khalifa University, Harvard Apparatus Regenerative Technology, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, Healios K.K., HealthBanks Biotech, Heartseed, HekaBio, Helix BioPharma, Helmholtz Zentrum Munchen, HemaCare, HemispheRx Biopharma, Hemogenyx, Henry Schein, HepaTx, Hepregen, Heraeus, HiFiBio, Histogen, Histogenics, Histogen Oncology, Hitachi Chemical, HitGen, Hoba Therapeutics, Hong Kong Baptist University, Horama, Horizon 2020, Horizon Discovery, Hoth Therapeutics, Hough Ear Institute, HSRx Group, HTG Molecular Diagnostics, Huapont Pharma, Hugel, Humanigen, Human Life CORD Japan, Human Longevity, Huntsworth Health, Icahn School of Medicine at Mount Sinai, Icon, Ideal Medical Solutions, IDIS Pharma, ID Pharma, Immatics Biotechnologies, ImmuneCyte Life Sciences, Immune Therapeutics, ImmunoCellular Therapeutics, ImmunXperts, Immusol, Imperial Innovations, IMV, Incyte, Indapta Therapeutics, Indiana University, Induce Biologics, Inform Genomics, Inhibrx, Innate Pharma, Innovate UK, Innovative Cellular Therapeutics, Innovative Genomics Initiative (IGI), Inserm Transfert, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Cancer Research, Institute of Child Health, Institute of Endocrinology, Metabolism, and Reproduction, Institute Of Molecular Biotechnology, Institut Pasteur, Integra LifeSciences, Intellia Therapeutics, IntelliCell BioSciences, International Duchenne Alliance, International Society for Cellular Therapy, International Stem Cell, Intrexon, inVentiv Health, Invetech, Invigorcell, Invitae, InVivo Therapeutics, INVO Bioscience, Ion Channel Innovations, Iovance Biotherapeutics, iPS Academia Japan, ISIS Innovation, Isogenica, Israeli National Authority for Technological Innovation, Itochu, Iveric Bio, Janssen Biotech, Janssen Pharmaceuticals, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, jCyte, Jiangsu Hengrui Medicine, John Hopkins University School of Medicines, Johns Hopkins University, Johnson & Johnson Innovation, Joslin Diabetes Center, JSR, Juno Therapeutics, Juvenile Diabetes Research Foundation, Juventas Therapeutics, Kadimastem, Kadmon Pharmaceuticals, Kangmei Pharma, KangStem Biotech, Karolinska Institute, Kasios, KBI BioPharma, Kerecis, Kiadis Pharma, Kinetic Concepts, Kinetic River, Kings College London, Kite Pharma, Kleo Pharmaceuticals, Kogenix, Kolon Life Science, Korea-Israel Industrial R&D Foundation, KSQ Therapeutics, KYERON Medical Innovations, Kyocera, Kyoto University, Kyverna Therapeutics, Laboratory Corporation of America, Lacerta Therapeutics, Lee Moffitt Cancer Center, Lehigh University, Leiden University, LEITAT, Lentigen, Leona M and Harry B Helmsley Charitable Trust, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, LifeCell, LifeLiver, LifeSouth Community Blood Centers, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, Live Like Bella Childhood Cancer Foundation, Liventa Biosciences, Locana, LogicBio Therapeutics, Longeveron, Lonza, Lorem Vascular, Loughborough University, Lubeck Institute of Experimental Dermatology, Lund University, Lung Biotechnology, Lupus Foundation of America (LFA), Luye Pharma Group, Lysogene, Lytix Biopharma, M-ERA.Net, MabVax Therapeutics, Macquarie University, MacroCure, Magenta Therapeutics, MAGiQ Therapeutics, Magnetic Insight, Magnum Cell Therapies, Malaghan Institute, Mallinckrodt Pharmaceuticals, MangoGen Pharma, Marasco Laboratory, Marken, Maryland Stem Cell Research Fund, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, MaSTherCell, Maverick Therapeutics, Max-Delbruck Center for Molecular Medicine, Max-Planck, Maxcyte, Mayo Clinic, McGill University, McKesson, MD Anderson Cancer Center, MDA Venture Philanthropy, Medac, Medeor Therapeutics, MedGenesis Therapeutix, Medgenics, Medical Incubator Japan, Medical Research Council, Medical Technology Enterprise Consortium, Medical University of Graz, Medicine by Design, Medifocus, MediGene, MedImmune, Medinet, Medipal Holdings, MediSix Therapeutics, Medison Pharma, Medisun International, Medpace, MeiraGTx, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Serono, Mesoblast, Metabolon, Metasurg, Methuselah Foundation, Metrion Biosciences, Michael J Fox Foundation, Microart, Microsoft, Mill Creek Life Sciences, MilliporeSigma, Milo Biotechnology, Miltenyi Biotec, Minerva Biotechnologies, MirImmune, Misonix, Mitsubishi Tanabe Pharma, Molecular Templates, MolMed, Monarch Biosciences, Montana Board of Research and Commercialization Technology, Morphogenesis, Mount Sinai Medical Center, Mount Tam Biotechnologies, MSM-Medimpex, MT-Biological Science and Technology, MTF Biologics, Multiclonal Therapeutics, Mundipharma, Munich Technical University, Murdoch Childrens Research Institute, Muscular Dystrophy Association, Mustang Bio, Myonexus Therapeutics, myTomorrows, Namocell, Nanion, Nano Dimension, nanoRanch, NanoString Technologies, Nanovis, NantKwest, Nanyang Technological University, NASA, Natera, National Cancer Centre Singapore, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Council on Aging, National Eye Institute, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institute on Disability and Rehabilitation Research, National Institutes of Health, National Institutes of Health Center for Regenerative Medicine, National Psoriasis Foundation, National Research Council of Canada, National Stem Cell Foundation, National Taiwan University Hospital, National University of Ireland, Galway (NUI Galway), National University of Singapore, Nationwide Children’s Hospital, Natural Sciences and Engineering Research Council of Canada, Ncardia, NEC, Neon Therapeutics, Nestle Health Science, Netherlands Cancer Institute, NetScientific, Neurocrine Biosciences, NeuroVigil, New Jersey Innovation Institute, New York Blood Center, New York Medical College, New York Presbyterian/Columbia, Neximmune, NHS Blood and Transplant, Nightstar Therapeutics, NightstaRx, Nikon CeLL Innovation, Nkarta Therapeutics, Nohla Therapeutics, Noile-Immune Biotech, North Carolina State University, Northern Biomedical Research, Northwestern University, Norwegian Research Council, Notch Therapeutics, Novartis, Novasep, Novellus Biopharma, Novo Nordisk, Nuclea Biotechnologies, NuGene International, Nuo Therapeutics, Nuvilex, Obsidian Therapeutics, Ocata Therapeutics, Ocugen, Ocumension Therapeutics, Odylia Therapeutics, Office of Naval Research, Ohio Clinical Trials Collaborative, Ohio State University, Olaregen Therapeutix, Omeros, Oncolys BioPharma, Oncora Medical, OncoSec Medical, oNKo-innate, ONK Therapeutics, Ono Pharmaceutical, Ophthotech, Orbit Biomedical, Orbsen Therapeutics, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, ORFLO Technologies, Organogenesis, Organovo, Organ Technologies, Orgenesis, Ori Biotech, ORIG3N, Orthocell, OrthoCyte, Orthohealing Center Management, Orthopaedic Research and Education Foundation, Ortho Regenerative Technologies, OSE Immunotherapeutics, Osiris Therapeutics, Ospedale San Raffaele, Osteo Science Foundation, Otologic Pharmaceutics, Oxford BioMedica, Oxford MEstar, Oxgene, OZ Biosciences, PACA Inovation, PacificGMP, Pall Corporation, Pan American Cancer Treatment Centers, panCELLa, Panion, Paragon Bioservices, Parcell Laboratories, Parent Project Muscular Dystrophy, Parnell Pharmaceutical Holdings, Passage Bio, Pathways to Stem Cell Science, Paul Ehrlich Institute, Paul G Allen Family Foundation, PCT, PDC*line Pharma, Perelman School of Medicine, Pfizer, PharmaCell, PharmaCyte Biotech, Phio Pharmaceuticals, Pivotal Scientific, PlantArcBio, PlasmaTech Biopharmaceuticals, PlasmidFactory, Plasticell, Platelet BioGenesis, Pluristem Therapeutics, Plus Therapeutics, Poietis, Population Diagnostics, Poseida Therapeutics, Prasco Laboratories, Precision BioSciences, Premier Inc, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, Procella Therapeutics, Progenitor Cell Therapy, ProMab Biotechnologies, Promethera Biosciences, Prometheus Laboratories, Propagenix, Prostate Cancer Clinical Trials Consortium, Prostate Cancer Foundation (PCF), Proteona, ProtoKinetix, Provecs Medical, Providence Cancer Institute, PsiOxus Therapeutics, PTC Therapeutics, Puregraft, Q Therapeutics, Quebec Consortium for Drug Discovery, Queensland Institute of Medical Research (QIMR), Ramot at Tel Aviv University, Recordati, Regen BioPharma, Regenerative Medicine of China, Regeneron Pharmaceuticals, Regeneus, Regentys, Regenxbio, ReGenX Biosciences, ReNeuron, Renovacare, Renova Therapeutics, Renovo, Replicel Life Sciences, ReproCell, Research Development Foundation, Research Institute of the Hospital Universitari Vall d'Hebron, Research Products Development Company, RetroSense Therapeutics, Revitope, Rexgenero, Ricoh, RIKEN Yokohama Institute Omics Science Center, Riyadh Pharma, Roche, Rockefeller University, Rocket Pharmaceuticals, Rockland Immunochemicals, Rohto Pharmaceutical, Roivant Sciences, RoosterBio, ROSLINCT, Roswell Park Cancer Institute, Royal Children’s Hospital, Royal Free Hospital, RTI Surgical, Rutgers University, RxBio, RXi Pharmaceuticals, SAFC, Salk Institute, Sana Biotechnology, SanBio, Sanford Health, Sangamo BioSciences, Sanofi, San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy, Santen Pharmaceutical, Santhera Pharmaceuticals, Sapreme Technologies, Sarepta Therapeutics, SAVSU Technologies, Scaled Biolabs, Schepens Eye Research Institute, ScinoPharm Taiwan, SCM Pharma, Scottish Enterprise, Scripps Research Institute, SeaSpine, Seattle Children's Hospital, Seattle Childrens Research Institute, Secant Medical, Seelos Therapeutics, Selecta Biosciences, Selexis, Semma Therapeutics, Sensorion, Senti Biosciences, SeouLin Bioscience, Seoul National University, Seraxis, Seres Therapeutics, Sharp Edge Labs, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shibuya Kogyo, Shire Pharmaceuticals, Sigilon Therapeutics, Sigma-Tau, Silver Creek Pharmaceuticals, Sinovant Sciences, Sirenas, Sirion Biotech, Sirona Biochem, SiSaf, Small Business Innovation Research, Smartwise, Solentim, Solid Biosciences, Somahlution, Sorrento Therapeutics, Sosei, SOTIO, Spark Therapeutics, Spectrum Pharmaceuticals, Spooner Girls Foundation, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Stem Cell Medicine, Stem Cell Network, StemCell Systems, Stemcell Technologies, Stemedica Cell Technologies, StemExpress, Stemlife, StemoniX, StimLabs, St Jude Medical, StrideBio, Stryker, Suneva Medical, Sunovion Pharmaceuticals, SunTerra Biotechnology, Super-T Cell Cancer, Surgical Specialties, Swedish Orphan Biovitrum, Symbiotix Biotherapies, SynGen, Synlogic, Synpromics, Synthego, Synthetic Genomics, Systagenix Wound Management, T-TOP Clinical Research, Tactiva Therapeutics, TaiGen Biotechnology, TaiRx, Takara Bio, Takeda Pharmaceutical, Talee Bio, Tamid Bio, TapImmune, Targazyme, Target ALS Foundation, Targovax, Tasly Pharmaceuticals, TauTona, Taxus Cardium Pharmaceuticals, Taxus Pharmaceuticals, Taysha Gene Therapies, TC BioPharm, TCR2 Therapeutics, Team Sanfilippo, Technology University Dresden, Teijin, Tel Aviv Sourasky Medical Center, Temple University, TeneoBio, Terumo BCT, Tesaro, Tessa Therapeutics, Teva Pharmaceutical Industries, TFS International, TGen Drug Development, The American Senior Housing Association, The Cell and Gene Therapy Unit, The Cyprus Institute of Neurology and Genetics, The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC), The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, TheraBiologics, Theracell, Theragene Pharmaceuticals, Therakine, Therapeutic Solutions International, Theravectys, The Regents of the University of California, Thermo Fisher Scientific, ThermoGenesis, Thiel Foundation, Thomas Jefferson University, Thorne Research, Thought Leadership & Innovation Foundation, Thrive Bioscience, Tianhe Stem Cell Biotechnologies, Tianjin CanSino Biotechnology, TiGenix, TissueGene, Tissue Genesis, Tissue Regeneration Systems, Tiziana Life Sciences, Tmunity Therapeutics, TNK Therapeutics, Tocagen, Torque Therapeutics, Touchlight, Trakcel, Transposagen Biopharmaceuticals, Treeway, Trianta, TriArm Therapeutics, Triumvira Immunologics, TScan Therapeutics, TTFactor, Tu Dresden, Tulane University, TxCell, UCL Business, UGA Biopharma, UK Cystic Fibrosis Gene Therapy Consortium, Ulster University, Ultragenyx Pharmaceuticals, UNeMed, UniQuest, UniQure, United Cargo, United Therapeutics, Universal Cells, Universite Laval, University Ann & Robert H. Lurie Children’s Hospital, University City Science Center, University College London, University Health Network, University Medical Center Groningen, University Medical Center Utrecht, University of Adelaide, University of Alabama, University of Alberta, University of Barcelona, University of Basel, University of Bern, University of Birmingham, University of British Columbia, University of California, University of California, Davis, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cologne, University of Colorado, University of Connecticut, University of Copenhagen, University of Eastern Finland, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Illinois at Chicago, University of Iowa, University of Kentucky, University of Lausanne, University of Leeds, University of Liverpool, University of Manchester, University of Maryland, University of Massachusetts, University of Massachusetts, Amherst, University of Massachusetts Medical School, University of Michigan, University of Milano-Bicocca, University of Minnesota, University of Missouri, University of Nebraska, University of North Carolina, University of North Texas Health Science Center, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Quebec, University of Queensland, University of Rhode Island, University of Rome, University of South Florida, University of Sydney, University of Technology Sydney, University of Tennessee, University of Texas Southwestern Medical Center, University of Tokyo, University of Toronto, University of Turin, University of Victoria-Genome British Columbia Proteomics Centre, University of Virginia, University of Washington, University of Wisconsin-Madison, University Pierre Marie Curie, Upside Biotechnologies, Urovant Sciences, US Army, US Army Institute of Surgical Research (USAISR), US Army Medical Research and Material Command, US Navy, US Stem Cell Clinic, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), Valitacell, Vascugen, Vault Bioventures, Vaximm, VBL Therapeutics (dba), Vectalys, Vedanta Biosciences, Velabs Therapeutics, Vericel, Vertex Pharmaceuticals, Vet-Stem, ViaCyte, VIB, Videregen, Vigene Biosciences, Vineti, ViraCyte, Vir Biotechnology, Virginia Catalyst, Virginia Commonwealth University, Visikol, VistaGen Therapeutics, Vital KSK, Vitruvian Networks, Vivet Therapeutics, ViVex Biomedical, Vivo Biosciences, Vizient, Vor Biopharma, Voyager Therapeutics, VWR International, Vycellix, Vyriad, Waisman Biomanufacturing, Wake Forest University, Walloon Region Investment Fund, Washington University in St Louis, WCTE, Weill Cornell Medical College, Wellcome Trust, Wellcome Trust Sanger Institute, Werum IT Solutions, Wilson Wolf, WindMIL Therapeutics, WIRB-Copernicus Group, Wistar Institute, Wize Pharma, W L Gore, Worcester Polytechnic Institute (WPI), WUGEN, Wuxi Apptec Laboratory Services, Wylde, Xcell Biosciences, Xencor, Xyphos, Y-Biologics, Yale University, Yeda Research and Development Company, YOFOTO (China) Health Industry, Yposkesi, YUMAB, Yumanity Therapeutics, Z-Medical, Zelluna Immunotherapy, Zenalux Biomedical, Zhaotai Group, Zhittya Genesis Medicine, Ziopharm Oncology

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.